COVID-19: Virtua Health continues to prioritize your safety. For information about services, testing, visiting, vaccines, and variants, click here.
COVID-19: Virtua Health continues to prioritize your safety. For information about services, testing, visiting, vaccines, and variants, click here.
Virtua’s reputation is built on providing access to the most advanced, state-of-the-art treatments for most conditions. We also offer some options that other healthcare providers don’t. These specific kinds of tests are called clinical trials, which are voluntary studies designed to evaluate new ways to prevent, diagnose and treat medical conditions.
Patients who participate in these studies receive the most recent approaches in care, developed by the nation’s foremost healthcare specialists. Many of today’s standard treatments of care began as clinical trials.
Explore the general (non-cancer) clinical trials that are open to Virtua patients. Continue to visit this page frequently as more general clinical trials are added to the list. View List >
Virtua’s affiliation with Penn Medicine allows Virtua’s patients to have access to the latest advances in cancer care, treatment, and research. Clinical trials are designed to evaluate new methods of cancer prevention and treatment that are are approved by the National Cancer Institute.
View a listing of available clinical trials that are provided.
If you have questions about clinical trials, please call a Virtua cancer research coordinator:
Virtua Samson Cancer Center: 856-206-4721
Virtua Voorhees Hospital: 856-247-7395
As with all types of care at Virtua, your safety is first and foremost, and many safeguards are in place should you choose to participate in one of our clinical trials. One of the most important of these is the Institutional Review Board (IRB), a group that reviews studies before they begin to ensure that potential benefits outweigh risks. This group also monitors data during the studies. The National Cancer Institute (NCI) provides another safeguard by reviewing all studies funded by the federal government. All risks and concerns about your treatment during the clinical trial would be thoroughly explained to you, and you would be asked to sign paperwork indicating that you understand how the process works and have given your full consent.
Oncology IRB
The Oncology IRB consists of doctors, radiation oncologist, oncology nurse, representative from the American Cancer Society, hospital administrator, member of the clergy and at least one lay member. Their mission is to choose cancer clinical research trials that will result in improved outcomes with the least amount of adverse events.
General Medical IRB
The general medical IRB at Virtua focuses on trials for treatments that range from new medications for everything from heart attacks to pain management. Similar to the oncology IRB, this group is comprised of a diverse group of experts who review studies before they begin to ensure that potential benefits outweigh risks. They also monitor data during the studies to ensure the treatment’s safety.
For more information about Virtua’s clinical trial programs, call 1-888-VIRTUA-3 (1-888-847-8823).
Potential or current investigators in a research study that is funded by the Public Health Service (PHS) must comply with Virtua’s policy entitled, “Virtua Public Health Service (PHS) Research Financial Conflict of Interest Policy.” The term investigator means any individual who is responsible for the design, conduct, or reporting of PHS sponsored research, or proposals for such funding. This definition is not limited to those titled or budgeted as principal investigator or co-investigator on a particular proposal, and may include postdoctoral associates, senior scientists, or graduate students. The definition may also include collaborators or consultants as appropriate. The policy must be adhered to prior to submitting a request for research funding to any Public Health Service funding source and through all time points identified in the policy.
Questions regarding this policy may be directed to researchreview@virtua.org.